Underdiagnosis of chronic obstructive pulmonary disease in women: Quantification of the problem, determinants and proposed actions;Infradiagnóstico de la enfermedad pulmonar obstructiva crónica en mujeres: Cuantificación del problema, determinantes y propuestas de acción

Archivos de Bronconeumologia

Volumn 49, Issue 6, 2013, Pages 223-229

  Ancochea, Julio ^a   Miravitlles, Marc ^b   García Río, Francisco ^c   Muñoz, Luis ^d   Sánchez, Guadalupe ^e   Sobradillo, Víctor ^f   Duran Tauleria, Enric ^g   Soriano, Joan B ^h  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^h Laboratory of Microbial Pathogenesis   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Gender; Spain; Spirometry; Tobacco; Underdiagnosis

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIAGNOSTIC ERROR; DISEASE SEVERITY; DYSPNEA; EDUCATIONAL STATUS; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREVALENCE; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; SMOKING; SPIROMETRY; SPUTUM; SYMPTOM; WHEEZING; WOMEN'S HEALTH; AGE; ENVIRONMENTAL EXPOSURE; SEX RATIO; SPANIARD; UNDERDIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DELAYED DIAGNOSIS; EDUCATIONAL STATUS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SAMPLING STUDIES; SEX DISTRIBUTION; SMOKING; SPAIN; SPIROMETRY; SYMPTOM ASSESSMENT;

EID: 84878012485     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2012.11.010     Document Type: Article

References (38)

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 [consultado 31 Dic 2011]. Disponible en: . http://www.goldcopd.org/.
2. Soriano J.B., Miravitlles M. Datos epidemiológicos en España. Arch Bronconeumol 2007, 43(Supl 1):2-10.
3. Miravitlles M., de la Roza C., Naberán K., Lamban M., Gobartt E., Martín A., et al. Problemas con el diagnóstico de la EPOC en atención primaria. Arch Bronconeumol 2006, 42:3-8.
4. Varkey A.B. Chronic obstructive pulmonary disease in women: exploring gender differences. Curr Opin Pulm Med 2004, 10:98-103.
5. Cote C.G., Chapman K.R. Diagnosis and treatment considerations for women with COPD. Int J Clin Pract 2009, 63:486-493.
6. Van Haren-Willems J., Heijdra Y. Increasing evidence for gender differences in chronic obstructive pulmonary disease. Womens Health (Lond Engl) 2010, 6:595-600.
7. De Torres Tajes J.P., Casanova C. Enfermedad pulmonar obstructiva crónica en mujeres. Arch Bronconeumol 2010, 46(Supl 3):23-27.
8. Raherison C., Biron E., Nocent-Ejnaini C., Taillé C., Tillie-Leblond I., Prudhomme A. Are there specific characteristics of COPD in women?. Rev Mal Respir 2010, 27:611-624.
9. Miravitlles M., Soriano J.B., Garcia-Rio R., Muñoz L., Duran-Tauleria E., Sanchez G., et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009, 64:863-868.
10. Sobradillo-Peña V., Miravitlles M., Gabriel R., Jiménez-Ruiz C.A., Villasante C., Masa J.F., et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000, 118:981-989.
11. Soriano J.B., Ancochea J., Miravitlles M., García-Río F., Duran-Tauleria E., Muñoz L., et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J 2010, 36:758-765.
12. Soriano J.B., Miravitlles M., Borderías L., Duran-Tauleria E., García Río F., Martínez J., et al. Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors. Arch Bronconeumol 2010, 46:522-530.
13. Menezes A.M., Perez-Padilla R., Jardim J.R., Muino A., Lopez M.V., Valdivia G., et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881. PLATINO Team.
14. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741-750. BOLD Collaborative Research Group.
15. Ancochea J., Badiola C., Duran-Tauleria E., Garcia Rio F., Miravitlles M., Muñoz L., et al. Estudio EPI-SCAN: resumen del protocolo de un estudio para estimar la prevalencia de EPOC en personas de 40 a 80 años en España. Arch Bronconeumol 2009, 45:41-47.
16. Minette A., Aresini G., Sanna-Randaccio F., Seaton A., Smidt U., Teculescu D. Cuestionario CECA para el estudio de los síntomas respiratorios, 1987 1988, Comisión de las Comunidades Europeas, Luxemburgo. 3.a ed.
17. Miller M.R., Hankison J., Brusasco V., Burgos R., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
18. Quanjer P., Tammeling G., Cotes J., Pedersen O., Peslin R., Yernault J. Official Statement of the European Respiratory Society. Eur Respir J 1993, (Suppl 16):5-40. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal.
19. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. ATS/ERS Task Force.
20. Centro Nacional de Epidemiología. Servidor Raziel. Disponible en: [consultado 17 Oct 2012]. http://193.146.50.130/raziel.php.
21. Shafey O., Erisksen M., Ross H., MacKay J. The Tobacco Atlas 2009, American Cancer Society and the World Lung Foundation.
22. Tálamo C., de Oca M.M., Halbert R., Perez-Padilla R., Jardim J.R., Muiño A., et al. Diagnostic labeling of COPD in five Latin American cities. Chest 2007, 131:60-67. PLATINO team.
23. Encuesta Nacional de Salud 2009, Ministerio de Salud, Política Social, Ministerio de Sanidad y Política Social, Madrid, Disponible en: http://www.msc.es/estadEstudios/estadisticas/encuestaNacional/home.htm [consultado 17 Oct 2012].
24. Encuesta Europea de Salud en España. Avance de resultados del segundo y tercer trimestre de 2009. Disponible en: [consultado 17 Oct 2012]. http://www.ine.es/prensa/np582.pdf.
25. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Mortalidad. España y Comunidades Autónomas. Mortalidad por causas y sexo (1989-1998). Disponible en: [consultado 17 Oct 2012]. http://cne.isciii.es/mortal/mortal98/Cau8098.html.
26. European Lung White Book 2003, European Respiratory Society, European Respiratory Society Journals Ltd, Huddersfield.
27. Casas Méndez L.F., Montón Soler C., Baré Mañas M., Casabon Salas J., Pomares Amigó X., Aguirre Larracoechea U. Hospital de día de enfermedades respiratorias: impacto sobre la tasa de ingresos hospitalarios por exacerbaciones de la enfermedad pulmonar obstructiva crónica. Med Clin (Barc) 2011, 136:665-668.
28. Siafakas N.M., Vermeire P., Pride N.B., Paoletti P., Gibson J., Howard P., et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1398-1420.
29. Quanjer P., Stanojevic S., Cole T.J., Baur X., Hall G.L., Culver B., et al. Multi-ethnic reference values for spirometry for the 3-95 year age range: The Global Lung Function 2012 Equations. Report of the Global Lung Function Initiative (GLI), ERS Task Force to establish improved Lung Function Reference Values. ERJ 2012, 40:1324-1343. and the ERS Global Lung Function Initiative.
30. Boletín Oficial del Estado. Ley 42/2010, de 30 de diciembre, por la que se modifica la Ley 28/2005, de 26 de diciembre, de medidas sanitarias frente al tabaquismo y reguladora de la venta, el suministro, el consumo y la publicidad de los productos del tabaco.
31. Instituto Nacional de Estadística [consultado Feb 2007]. Disponible en: . http://www.inebase.es/.
32. Naberán K., Azpeitia A., Cantoni J., Miravitlles M. Impairment of quality of life in women with chronic obstructive pulmonary disease. Respir Med 2012, 106:367-373.
33. Miravitlles M., Ferrer M., Pont A., Viejo J.L., Masa J.F., Gabriel R., et al. Characteristics of a population of COPD patients identified from a population-based study. Focus on previous diagnosis and never smokers. Respir Med 2005, 99:985-995.
34. Soriano J.B., Zielinski J., Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009, 374:721-732.
35. Vestbo J., Soriano J.B., Anderson J.A., Calverley P., Pauwels R., Jones P. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 2004, 98:1045-1050. TRISTAN Study Group.
36. Gross N.J., Giembycz M.A., Rennard S.I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010, 7:141-153.
37. Gelberg J., McIvor R.A. Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights. Drugs Aging 2010, 27:367-375.
38. Llauger Roselló M.A., Pou M.A., Domínguez L., Freixas M., Valverde P., Valero C. Atención a la EPOC en el abordaje al paciente crónico en atención primaria. Arch Bronconeumol 2011, 47:561-570. Grup Emergent de Recerca en Malalties Respiratòries (Unitat de Suport a la Recerca de Barcelona-IDIAP Jordi Gol).